• Using a fluorescence tracking method in live mice, we show that SapC-DOPS specifically targets human lung cancer xenografts, and that systemic therapy with SapC-DOPS induces tumor apoptosis and significantly inhibits tumor growth. (aacrjournals.org)
  • Recent research has shown that several genetic abnormalities play an important role in the development and growth of lung cancer and cancers of the thymus, and that it is possible to improve treatment success rates with drugs that specifically target some of the abnormal genes. (clinicaltrials.gov)
  • Researchers are interested in determining whether it is possible to analyze the genes of patients with lung cancer and cancers of the thymus in order to provide personalized treatment with drugs that target the specific gene abnormalities. (clinicaltrials.gov)
  • To evaluate the effectiveness of genetic analysis in determining targeted therapy for individuals with advanced non-small cell lung cancer, small cell lung cancer, and thymic cancer. (clinicaltrials.gov)
  • Individuals at least 18 years of age who have been diagnosed with either lung cancer or a cancer of the thymus that is not considered to be curable with the use of surgery or radiation therapy. (clinicaltrials.gov)
  • Recently, molecular targeted agents have been applied in the clinic and have shown groundbreaking results in specific patient groups epidermal growth factor receptor ( EGFR )-targeted therapy or an anaplastic lymphoma kinase ( ALK ) inhibitor in lung cancer, human epidermal growth factor receptor 2 ( HER2 )-directed therapy in breast cancer, and CD20-targeted therapy in B cell lymphoma). (mdpi.com)
  • With the discoveries of many actionable driver mutations such as activating EGFR mutations and ALK rearrangement in adenocarcinoma of the lung we have switched to classifying non-small cell lung cancer into different individual molecular subgroups based on the presence of a dominant driver mutation. (bmj.com)
  • Journal focusing on lung cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes. (dmoztools.net)
  • Molecular Pathology of Nervous System Tumors is of great value and utility for physicians and scientists involved with or interested in the up-to-date diagnosis and treatment of patients with brain tumors. (ebookee.org)
  • The main limitation of the evidence for survival outcomes was inconsistency of effects across the studies, which we could not explain by prespecified subgroups in terms of the type of therapy or tumor type. (cochrane.org)
  • Finally smoking history may have predictive and/or prognostic significance within individual molecular subgroups and identifying the difference according to smoking history may help optimise future targeted therapy. (bmj.com)
  • Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. (nih.gov)
  • However, the sensitivity and reliability of such biomarkers may be complicated by mutations in the BRCA1 or BRCA2 genes, diverse genetic risk factors, unidentified initiation and progression elements, molecular tumor heterogeneity and disease staging. (nih.gov)
  • The aim of this review is to profile recent developments in our understanding of the interrelationships among selected ovarian tumor biomarkers, heterogeneous expression signatures and related molecular signal transduction pathways, and their translation into more efficacious targeted treatment rationales. (nih.gov)
  • Molecular biomarkers in urine may serve as important diagnostic and prognostic indicators for. (bioportfolio.com)
  • The extent of testing will be updated to reflect new discoveries in melanoma tumourigenesis and availability of new therapies as the project proceeds. (clinicaltrials.gov)
  • These patients will first receive standard of care therapy for wild type BRAF / NRAS melanoma, where possible. (clinicaltrials.gov)
  • Patients may be included in specific clinical trials of targeted therapies if available, e.g. a MEK inhibitor combined with an MDM2 inhibitor (AMG232) for BRAF and TP53 wild-type melanoma or a MEK inhibitor combined with a CDK4/6 inhibitor for BRAF wild-type melanoma. (clinicaltrials.gov)
  • In summary, the melanoma gene expression phenotypes are highly predictive of survival outcome and can further help to discriminate patients responding to targeted therapy. (harvard.edu)
  • Francesca Maira, Alessia Catania, Saverio Candido, Alessia Erika Russo, James A. McCubrey, Massimo Libra, Grazia Malaponte and Concettina Fenga, " Molecular Targeted Therapy in Melanoma: A Way to Reverse Resistance to Conventional Drugs", Current Drug Delivery (2012) 9: 17. (eurekaselect.com)
  • Starting from sorafenib and sunitinib, several targeted therapies have been approved for mRCC treatment, with a long list of agents in course of evaluation, such as tivozanib, cediranib, and VEGF-Trap. (hindawi.com)
  • Molecular diagnostics company providing laboratory testing for cancer genomics and pharmacogenomics, as well as forensic toxicology. (dmoztools.net)
  • Several signaling pathways are involved in tumor angiogenesis, such as VEGF, which plays a crucial role in RCC carcinogenesis [ 6 , 7 ], PDGF, the mammalian target of rapamycin (mTOR), VHL, a tumor suppressor gene, and HIF (Figure 1 ). (hindawi.com)
  • We concentrated on the most common classes of targeted therapies investigated in rhabdomyosarcoma to date, including those directed against receptor tyrosine kinases and associated downstream signaling pathways, the Hedgehog signaling pathway, apoptosis pathway, DNA damage response, cell-cycle regulators, oncogenic fusion proteins, and epigenetic modifiers. (aacrjournals.org)
  • There are just too many pathways in a cancer cell that can bypass the pathway addressed by the targeted therapy of interest. (aacrjournals.org)
  • there may be a myriad of pathways ahead, unknown to us, but well known to the cancer cell in need to bypass our targeted therapies. (aacrjournals.org)
  • Monotherapy of TKIs is recommended as the first-line management, and combination therapy (two TKIs or TKI plus mTOR inhibitor) may be the choice for drug-resistant chordoma. (frontiersin.org)
  • Understanding how the intricate signaling networks of cells and tissues allow cancer to thrive - and how they can be turned into potent weapons against it - is the key to managing cancer in the clinic and improving the outcome of cancer therapies. (libreriasaulamedica.com)
  • Botanicals have been shown to influence multiple biochemical and molecular cascades that inhibit mutagenesis, proliferation, induce apoptosis, suppress the formation and growth of human cancers, thus modulating several hallmarks of carcinogenesis. (omicsonline.org)
  • The main areas of research conducted by Bert Wolterbeek's Radiation and Isotopes for Health team at TU Delft involve innovative approaches for the optimization of radiation and isotopes for medical imaging and therapy. (tudelft.nl)
  • There is thus a dire need to expand existing ovarian cancer therapies with broad-spectrum and individualized molecular targeted approaches. (nih.gov)
  • Nevertheless, despite recent success, complete responses to antiangiogenic therapies are rare, and patients do progress in response to antivascular endothelial growth factor (VEGF) targeted therapies. (hindawi.com)
  • In this project, patients will have tumour tissue genetically profiled to determine which mutation(s) are present, and will then be assigned to receive a matched drug expected to target the mutation(s) in the tumour. (clinicaltrials.gov)
  • Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer. (bioportfolio.com)
  • Although obesity is a risk factor for breast cancer, little effort has been made in the identification of druggable molecular alterations in obese-breast cancer patients. (bioportfolio.com)
  • Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. (springer.com)
  • Nynke Dekker and her team at TU Delft's Kavli Institute of Nanoscience look at DNA and RNA protein interactions at the molecular level. (tudelft.nl)